Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia | Markets Insider
Source:
Buzz FX
/
23 Apr 2024 01:56:19 America/New_York
N/A
Share on,